

# Contents

<b>Interpreting the Flexibilities Under the TRIPS Agreement</b> . . . . .	1
Carlos M. Correa	
<b>Intellectual Property Exhaustion and Parallel Imports of Pharmaceuticals: A Comparative and Critical Review</b> . . . . .	31
Irene Calboli	
<b>Compulsory Licenses and Government Use: Challenges and Opportunities</b> . . . . .	73
Yousuf A. Vawda	
<b>Access to CRISPR Genome Editing Technologies: Patents, Human Rights and the Public Interest</b> . . . . .	105
Duncan Matthews	
<b>Bolar Exception</b> . . . . .	135
Viviana Munoz Tellez	
<b>Patent Oppositions in India</b> . . . . .	151
Sandeep Kanak Rathod	
<b>Protection of Clinical Test Data and Public Health: A Proposal to End the Stronghold of Data Exclusivity</b> . . . . .	183
Ellen 't Hoen	
<b>Courts and Pharmaceutical Patents: From Formalist Positivism to the Emergence of a Global Law</b> . . . . .	201
Calixto Salomão Filho and Vitor Henrique Pinto Ido	
<b>Robust Patent Examination or Deep Harmonization? Cooperation and Work Sharing Between Patent Offices</b> . . . . .	241
Nirmalya Syam	

<b>Intellectual Property Rights (IPRs), Competition Law and Excessive Pricing of Medicines . . . . .</b>	<b>277</b>
Mor Bakhoum	
<b>The Impact of ‘TRIPS-Plus’ Rules on the Use of TRIPS Flexibilities: Dealing with the Implementation Challenges . . . . .</b>	<b>297</b>
Mohammed El Said	
<b>Patent Linkages and Its Impact on Access to Medicines: Challenges, Opportunities for Developing Countries . . . . .</b>	<b>329</b>
K. D. Raju	